176 related articles for article (PubMed ID: 20213318)
1. Abelson virus transformation prevents TRAIL expression by inhibiting FoxO3a and NF-kappaB.
Wilson MK; McWhirter SM; Amin RH; Huang D; Schlissel MS
Mol Cells; 2010 Apr; 29(4):333-41. PubMed ID: 20213318
[TBL] [Abstract][Full Text] [Related]
2. Active FKHRL1 overcomes imatinib resistance in chronic myelogenous leukemia-derived cell lines via the production of tumor necrosis factor-related apoptosis-inducing ligand.
Kikuchi S; Nagai T; Kunitama M; Kirito K; Ozawa K; Komatsu N
Cancer Sci; 2007 Dec; 98(12):1949-58. PubMed ID: 17900262
[TBL] [Abstract][Full Text] [Related]
3. STI571 reduces TRAIL-induced apoptosis in colon cancer cells: c-Abl activation by the death receptor leads to stress kinase-dependent cell death.
Huang DY; Chao Y; Tai MH; Yu YH; Lin WW
J Biomed Sci; 2012 Mar; 19(1):35. PubMed ID: 22462553
[TBL] [Abstract][Full Text] [Related]
4. TGF-beta-FOXO signalling maintains leukaemia-initiating cells in chronic myeloid leukaemia.
Naka K; Hoshii T; Muraguchi T; Tadokoro Y; Ooshio T; Kondo Y; Nakao S; Motoyama N; Hirao A
Nature; 2010 Feb; 463(7281):676-80. PubMed ID: 20130650
[TBL] [Abstract][Full Text] [Related]
5. Pristimerin induces apoptosis in imatinib-resistant chronic myelogenous leukemia cells harboring T315I mutation by blocking NF-kappaB signaling and depleting Bcr-Abl.
Lu Z; Jin Y; Chen C; Li J; Cao Q; Pan J
Mol Cancer; 2010 May; 9():112. PubMed ID: 20482842
[TBL] [Abstract][Full Text] [Related]
6. IL-7 reconstitutes multiple aspects of v-Abl-mediated signaling.
Banerjee A; Rothman P
J Immunol; 1998 Nov; 161(9):4611-7. PubMed ID: 9794389
[TBL] [Abstract][Full Text] [Related]
7. TRAIL is involved in CpG ODN-mediated anti-apoptotic signals.
Lim EJ; Park DW; Jeong TW; Chin BR; Bae YS; Baek SH
Oncol Rep; 2012 Apr; 27(4):1213-8. PubMed ID: 22159760
[TBL] [Abstract][Full Text] [Related]
8. Purified vitexin compound 1 induces apoptosis through activation of FOXO3a in hepatocellular carcinoma.
Wang JG; Zheng XX; Zeng GY; Zhou YJ; Yuan H
Oncol Rep; 2014 Jan; 31(1):488-96. PubMed ID: 24247909
[TBL] [Abstract][Full Text] [Related]
9. Growth, differentiation, and malignant transformation of pre-B cells mediated by inducible activation of v-Abl oncogene.
Jacobsen EA; Ananieva O; Brown ML; Chang Y
J Immunol; 2006 Jun; 176(11):6831-8. PubMed ID: 16709843
[TBL] [Abstract][Full Text] [Related]
10. Imatinib reverses doxorubicin resistance by affecting activation of STAT3-dependent NF-κB and HSP27/p38/AKT pathways and by inhibiting ABCB1.
Sims JT; Ganguly SS; Bennett H; Friend JW; Tepe J; Plattner R
PLoS One; 2013; 8(1):e55509. PubMed ID: 23383209
[TBL] [Abstract][Full Text] [Related]
11. A member of Forkhead transcription factor FKHRL1 is a downstream effector of STI571-induced cell cycle arrest in BCR-ABL-expressing cells.
Komatsu N; Watanabe T; Uchida M; Mori M; Kirito K; Kikuchi S; Liu Q; Tauchi T; Miyazawa K; Endo H; Nagai T; Ozawa K
J Biol Chem; 2003 Feb; 278(8):6411-9. PubMed ID: 12456669
[TBL] [Abstract][Full Text] [Related]
12. The antiproliferation effect of berbamine on k562 resistant cells by inhibiting NF-kappaB pathway.
Wei YL; Liang Y; Xu L; Zhao XY
Anat Rec (Hoboken); 2009 Jul; 292(7):945-50. PubMed ID: 19548306
[TBL] [Abstract][Full Text] [Related]
13. GILZ inhibits the mTORC2/AKT pathway in BCR-ABL(+) cells.
Joha S; Nugues AL; Hétuin D; Berthon C; Dezitter X; Dauphin V; Mahon FX; Roche-Lestienne C; Preudhomme C; Quesnel B; Idziorek T
Oncogene; 2012 Mar; 31(11):1419-30. PubMed ID: 21804606
[TBL] [Abstract][Full Text] [Related]
14. FOXO3A as a key molecule for all-trans retinoic acid-induced granulocytic differentiation and apoptosis in acute promyelocytic leukemia.
Sakoe Y; Sakoe K; Kirito K; Ozawa K; Komatsu N
Blood; 2010 May; 115(18):3787-95. PubMed ID: 20215638
[TBL] [Abstract][Full Text] [Related]
15. Cotreatment with STI-571 enhances tumor necrosis factor alpha-related apoptosis-inducing ligand (TRAIL or apo-2L)-induced apoptosis of Bcr-Abl-positive human acute leukemia cells.
Nimmanapalli R; Porosnicu M; Nguyen D; Worthington E; O'Bryan E; Perkins C; Bhalla K
Clin Cancer Res; 2001 Feb; 7(2):350-7. PubMed ID: 11234890
[TBL] [Abstract][Full Text] [Related]
16. miR290-5p/292-5p activate the immunoglobulin kappa locus in B cell development.
Garcia PB; Cai A; Bates JG; Nolla H; Schlissel MS
PLoS One; 2012; 7(8):e43805. PubMed ID: 22928038
[TBL] [Abstract][Full Text] [Related]
17. Direct transcriptional regulation of Bim by FoxO3a mediates STI571-induced apoptosis in Bcr-Abl-expressing cells.
Essafi A; Fernández de Mattos S; Hassen YA; Soeiro I; Mufti GJ; Thomas NS; Medema RH; Lam EW
Oncogene; 2005 Mar; 24(14):2317-29. PubMed ID: 15688014
[TBL] [Abstract][Full Text] [Related]
18. Targeting 14-3-3 sensitizes native and mutant BCR-ABL to inhibition with U0126, rapamycin and Bcl-2 inhibitor GX15-070.
Dong S; Kang S; Lonial S; Khoury HJ; Viallet J; Chen J
Leukemia; 2008 Mar; 22(3):572-7. PubMed ID: 18079735
[TBL] [Abstract][Full Text] [Related]
19. A Bcr/Abl-independent, Lyn-dependent form of imatinib mesylate (STI-571) resistance is associated with altered expression of Bcl-2.
Dai Y; Rahmani M; Corey SJ; Dent P; Grant S
J Biol Chem; 2004 Aug; 279(33):34227-39. PubMed ID: 15175350
[TBL] [Abstract][Full Text] [Related]
20. IkappaB kinase beta inhibition induces cell death in Imatinib-resistant and T315I Dasatinib-resistant BCR-ABL+ cells.
Duncan EA; Goetz CA; Stein SJ; Mayo KJ; Skaggs BJ; Ziegelbauer K; Sawyers CL; Baldwin AS
Mol Cancer Ther; 2008 Feb; 7(2):391-7. PubMed ID: 18245668
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
